Boston Scientific Corporation (NYSE:BSX) witnessed a selling pressure and the shares last traded with a loss of -0.12 points or -0.53% at $22.71. Investors jumped in to buy the shares on weakness. The net money flow till latest update was calculated at $14.16 million with an inflow of $31.09 million in upticks and an outflow of $16.93 million in downticks. Using the data, the up/down ratio is found to be 1.84. The share price has recorded -1.35% on a weekly basis.A block trade of $19.48 million in uptick and $4.1 million in downtick was also observed, resulting in an up/down ratio of 4.75. The net money flow of the block trade stood at a $15.38, signaling heavy buying.
Boston Scientific Corporation has dropped 2.3% in the last five trading days, however, the shares have posted positive gains of 0.9% in the last 4 weeks. Boston Scientific Corporation is up 24.12% in the last 3-month period. Year-to-Date the stock performance stands at 21.96%.
Currently the company Insiders own 1.31% of Boston Scientific Corporation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -20.95% . Institutional Investors own 93.31% of Boston Scientific Corporation shares. During last six month period, the net percent change held by insiders has seen a change of -21.18%. . On the companys insider trading activities, The officer (EVP, GC & Chief Admin Officer), of Boston Scientific Corp, Pratt Timothy A. had unloaded 24,229 shares at $22.66 per share in a transaction on June 1, 2016. The total value of transaction was $549,029. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Boston Scientific Corporation (NYSE:BSX) witnessed a decline in the market cap on Friday as its shares dropped 1.49% or 0.34 points. After the session commenced at $22.87, the stock reached the higher end at $22.91 while it hit a low of $22.32. With the volume soaring to 40,495,410 shares, the last trade was called at $22.49. The company has a 52-week high of $23.35. The company has a market cap of $30,516 million and there are 1,356,866,900 shares in outstanding. The 52-week low of the share price is $14.1801.
Boston Scientific Corporation develops, manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology, which includes Drug-Eluting Coronary Stent Systems, Intravascular Imaging devised and Coronary Technology products, such as guide wires, guide catheters, and balloon catheters, among others; Peripheral Interventions (PI), which include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM), which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP), which include steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories; Endoscopy, which includes Spyglass System, WallFlex Colonic Stents, Resolution Clip, and Expect Aspiration Needle, among others; Urology and Womens Health, and Neuromodulation.